Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer
Austin G. Duffy(National Institutes of Health), Tim F. Greten(National Institutes of Health)
Cited by 73